In biopharma, the report found that 64 percent of investors said that they were more likely to acquire early-stage, innovative companies in 2023, according to a Jan. 9 KPMG news release.
“2022 is a story of both tailwinds and headwinds,” Ash Shehata, KPMG national sector leader healthcare and life sciences, said. “Hospital systems are dealing with rising labor and supply costs while biopharma and medical device companies have been exposed to supply chain, logistics, and labor issues that slow down production. Now is the time for [healthcare and life sciences] leaders to adjust their strategies to build durability and resilience within their companies.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.